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Background: There is limited consensus among drug information sources on what constitutes drug-drug interactions
(DDIs). We investigate DDI information in two publicly available sources, NDF-RT and DrugBank.
Methods: We acquire drug-drug interactions from NDF-RT and DrugBank, and normalize the drugs to RxNorm. We
compare interactions between NDF-RT and DrugBank and evaluate both sources against a reference list of 360 critical
interactions. We compare the interactions detected with NDF-RT and DrugBank on a large prescription dataset. Finally,
we contrast NDF-RT and DrugBank against a commercial source.
Results: DrugBank drug-drug interaction information has limited overlap with NDF-RT (24-30%). The coverage of
the reference set by both sources is about 60%. Applied to a prescription dataset of 35.5M pairs of co-prescribed
systemic clinical drugs, NDF-RT would have identified 808,285 interactions, while DrugBank would have identified
1,170,693. Of these, 382,833 are common. The commercial source Multum provides a more systematic coverage
(91%) of the reference list.
Conclusions: This investigation confirms the limited overlap of DDI information between NDF-RT and DrugBank.
Additional research is required to determine which source is better, if any. Usage of any of these sources in
clinical decision systems should disclose these limitations.
Keywords: Drug-drug interactions, NDF-RT, DrugBankBackground
Motivation
An important component of electronic health record
systems is the use of clinical decision support (CDS) to
improve medication safety [1,2]. Preventable adverse
drug reactions include those resulting from drug-drug
interactions (DDIs) [3,4]. Among other things, CDS sys-
tems leverage drug-drug interaction information to re-
duce the possibility of adverse drug events [5,6]. While
there are many sources of DDI information, and many
commercially available systems which contain this infor-
mation, there is limited consensus on what constitutes
critical and non-critical DDI [7].
One source of publicly available DDI information is
contained in the National Drug File Reference Termin-
ology (NDF-RT) and available through the NDF-RT appli-
cation programming interface (API). Several applications* Correspondence: obodenreider@mail.nih.gov
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unless otherwise stated.developed for medication management take advantage of
the API for checking interactions in medication lists (e.g.,
the iOS app “Dosage” for medication information and re-
minders). However, it was announced before the writing
of this article that the DDI information would be soon re-
moved from NDF-RT [8]. Our search for another publicly
available source of DDI information led us to evaluate the
DrugBank data source as a possible replacement for the
NDF-RT DDIs.
In this paper, our objective is to evaluate the DDI in-
formation in NDF-RT and DrugBank. More specifically,
we contrast NDF-RT and DrugBank interactions against
each other, and contrast both against a previously pub-
lished reference set of critical DDIs [9]. We also contrast
NDF-RT and DrugBank in their ability to detect DDIs in
a large prescription dataset. Finally, we compare the
coverage of the reference set by DrugBank and NDF-RT
to that of a commercial source.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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The following sections detail the characteristics of the
drug information sources used in this research. We use
RxNorm to harmonize drugs between the two sources of
DDIs under investigation, NDF-RT and DrugBank.
NDF-RT
The National Drug File Reference Terminology (NDF-RT)
is a resource developed by the Department of Veterans
Affairs (VA) Veterans Health Administration, as an exten-
sion of the VA National Drug File [10]. It is updated
monthly. NDF-RT covers 7319 active moieties (level = in-
gredient). In addition to providing information about indi-
vidual drugs (e.g., mechanism of action, physiologic effect,
therapeutic intent), NDF-RT also provides a set of 10,831
drug-drug interactions (DDIs). DDIs are asserted at the
ingredient level and accompanied by a mention of severity
(significant or critical). For example, NDF-RT asserts a
critical interaction between omeprazole and clopidogrel
and asserts a significant interaction between diltiazem and
lovastatin. The version used in this study is dated July 7,
2014 and was accessed through the NDF-RT API [11].
(Provision of DDI information in NDF-RT was discontin-
ued in November 2014).
DrugBank
Developed with funding from Genome Canada, DrugBank
is a knowledge base containing “extensive biochemical
and pharmacological information about drugs, their
mechanisms and their targets” [12]. DrugBank covers
7683 active moieties. Although not primarily developed
for clinical use, DrugBank provides a set of 12,128 drug-
drug interactions (DDIs), asserted at the ingredient
level, along with a brief textual description of the inter-
action, and information about the possible molecular
basis of the interaction (target-based, enzyme-based,
transporter-based). For example, DrugBank asserts an
interaction between omeprazole and clopidogrel bisul-
fate, described as “Omeprazole may decrease serum
concentrations of the active metabolite(s) of clopido-
grel. Clopidogrel prescribing information recommends
avoiding concurrent use with omeprazole, due to the
possibility that combined use may result in decreased
clopidogrel effectiveness”. The possible molecular basis
of the interaction is reported to be enzyme-based or
transporter-based. The version used in this study (4.0) was
downloaded from the DrugBank website on July 1, 2014.
RxNorm
RxNorm is a standardized nomenclature for medications
produced and maintained by the U.S. National Library
of Medicine (NLM) [13]. While NDF-RT is one of the
drug information sources integrated in RxNorm, Drug-
Bank is not. However, most ingredients from DrugBankare covered by RxNorm and RxNorm can be used to
map drugs between DrugBank and NDF-RT. Moreover,
RxNorm provides a rich network of relations among
various types of drug entities. For example, RxNorm ex-
plicitly asserts that clopidogrel bisulfate is the “precise
ingredient” of the ingredient clopidogrel, making it pos-
sible to normalize the various salts and esters of a drug
to their base form. RxNorm also integrates the Anatom-
ical Therapeutic Chemical (ATC) classification, which
makes it possible to extract the ATC class for most
drugs. For example ATC classifies clopidogrel as a Plate-
let aggregation inhibitors excl. heparin. The July 2014
version of RxNorm is used in this study and was
accessed through the RxNorm API [14].
Related work
Extracting drug-drug interaction (DDI) information from
textual resources, such as the biomedical literature or
structured product labels is an active field of research
[15-18]. Other researchers predict DDIs from a variety of
resources [19].
As mentioned earlier, researchers have shown the
benefit of integrating DDI information in CPOEs (e.g.,
[1,2]). However, not all studies demonstrate improve-
ment on medication safety, especially due to the large
number of alerts produced by some systems [20], which
raises questions about the quality of the underlying DDI
information.
Given the limited consensus across sources of DDI in-
formation [7], researchers have proposed criteria for
assessing high-priority DDIs [21] and for calibrating
CDS systems [22]. An expert panel was convened to
identify high-severity, clinically significant DDIs for the
Office of the National Coordinator for Health Informa-
tion Technology (ONC) as part of the Meaningful Use
incentive program [9]. Candidate DDIs were assessed by
the panel based on a number of factors, including sever-
ity levels across medication knowledge bases, conse-
quences of the interaction, predisposing factors, and
availability of therapeutic alternatives. The resulting list
contains 360 interacting pairs of individual drugs con-
taining 86 unique drugs. This list will be referred to as
the reference set of DDIs in the following sections.
Specific contribution
The specific contribution of our work is to contrast two
publicly available sources of DDI information, NDF-RT
and DrugBank, through an assessment of the overlap of
their content, and of their coverage of a reference set of
DDIs. Moreover, we compare the ability of these two
sources to identify DDIs in a large prescription dataset,
and contrast them against a commercial source. To the
best of our knowledge, this is the first such comparative
investigation of NDF-RT and DrugBank DDI information.
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Our approach to evaluating drug-drug interaction (DDI)
information in NDF-RT and DrugBank can be summa-
rized as follows. We acquire the list of drug-drug inter-
actions in NDF-RT and DrugBank, as well as a reference
set of DDIs. We map all drugs from the three sets to
RxNorm and further normalize them to ingredient en-
tities. We then compare the lists of pairs of interacting
drugs across sources in order to determine the shared
coverage between NDF-RT and DrugBank, as well as the
coverage of the reference set by both sources. We
characterize the differences among DDI sets in terms of
drug classes. We also compare the interactions detected
with NDF-RT and DrugBank in a large prescription
dataset. Finally, we compare the coverage of the refer-




We used the NDF-RT API [11] to first extract the full
set of DDIs (DRUG_INTERACTION_KIND concepts),
then to extract each associated drug concept (level = in-
gredient) in the pair.
DrugBank
The DrugBank XML and schema definition files were
downloaded from the DrugBank web site. We extracted
the interaction data from the XML file and created a
table of drug name pairs for the interacting drugs.
Reference set
The reference set of DDIs was created from the drug
names listed in Table two of [9] by associating each ob-
ject drug with all corresponding precipitant drug(s)
within a given interaction class. One pair involving a
multi-ingredient drug (azathioprine and mercaptopu-
rine) was eliminated, because multi-ingredient drugs are
generally not consistently represented across sources.
Normalizing drugs in reference to RxNorm
After obtaining the drug name pairs for interacting
drugs, we mapped the drugs to RxNorm by retrieving
the RxNorm identifiers (RxCUIs). For NDF-RT, the
RxCUI is part of the drug’s concept properties, so we
used the NDF-RT API to extract the RxCUI from the
drug properties. For DrugBank and the reference set, we
used the RxNorm API [7] to find the RxCUI from the
drug name. More specifically, we used exact and nor-
malized string matches to map drug names to RxNorm.
We then “normalized” to RxNorm ingredients those
drugs which mapped to RxNorm entities. Some of the
drugs corresponded to base ingredients (e.g., doxacur-
ium), while others corresponded to salt forms thatRxNorm classifies as “precise ingredients” (e.g., doxacur-
ium chloride). In order to establish a consistent drug
representation across all three data sets for comparison,
we converted precise ingredients to RxNorm ingredients
(e.g., doxacurium chloride to doxacurium) using the
RxNorm API.
We eliminated from the comparison those pairs for
which at least one of the drugs could not be found in
RxNorm. For example, the DrugBank drug cerivastatin,
which was withdrawn from the U.S. market in 2001, is
not present in RxNorm.
Comparing interactions across sources
Having normalized all drugs to RxNorm ingredients, we
compared the lists from DDIs of NDF-RT and DrugBank
in order to determine the similarities and unique fea-
tures of each source. In addition, we compared each
with the reference set of DDIs to determine how many
of the reference DDIs each source covered.
Characterizing differences
To determine if there was a pattern of missing interac-
tions, we abstracted the pairs of interacting drugs into
pairs of classes from the Anatomical Therapeutic Chem-
ical (ATC) Classification System. We mapped the drugs
directly to their 4th-level ATC classes using the RxNorm
API and identified those pairs of ATC classes for which
the proportion of DDIs in common between NDF-RT
and DrugBank was low, using the Jaccard score. Of note,
some NDF-RT and DrugBank drugs are not represented
in ATC. So only DDIs for which both the object and
precipitant drugs are present in ATC were analysed.
Comparing coverage of interactions from actual
prescription data
In order to assess the difference between NDF-RT and
DrugBank interactions based on usage data, we collected
drug pairs generated from actual patient prescription lists.
Checking medication lists for drug-drug interactions repre-
sents a practical use case and is offered as a service by
many medication list applications. It also provides some
frequency of usage of the co-prescribed drug pairs extracted
from the lists. The data was acquired from Symphony
Health Solutions (http://symphonyhealth.com/). It included
one year of prescription data from the Washington, D.C.
area from July 1, 2011 through June 30, 2012. Prescrip-
tion information included prescriber, de-identified pa-
tient information, and specific medication information,
including the drug name and strength. The drug infor-
mation was mapped into RxNorm clinical drugs. From a
list of co-prescribed drugs, we generated all possible
pairwise combinations within the drug list (ignoring the
order of drugs in the pair, since the distinction between
object and precipitant drugs is not required for DDI
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list, because DDI information represented at the ingre-
dient level in NDF-RT and DrugBank usually refers to
interactions between systemic drugs. For example, we
generated the following pair of RxNorm clinical drug,
24 HR Diltiazem Hydrocloride 360 MG Extended Re-
lease Oral Capsule (830795) and Lovastatin 20 MG Oral
Tablet (197904). We mapped the clinical drugs to their
active moieties in RxNorm (Diltiazem Hydrocloride and
Lovastatin, respectively) and further normalized those
to RxNorm ingredients, as we did with all object and
precipitant drugs from the various DDI lists. Here, we
normalized Diltiazem Hydrocloride to Diltiazem. In
summary, we transformed the pair of RxNorm clinical
drugs extracted from the prescription list into the pair
of RxNorm ingredients (Diltiazem, Lovastatin) for com-
parison to the DDIs in NDF-RT and DrugBank.
Publicly available vs. commercial DDI sources
To compare the coverage of the reference set by Drug-
Bank and NDF-RT to that of a commercial source, we
investigated the Multum drug knowledge base through
the interaction checker of the website Drugs.com
(http://www.drugs.com/), against which we tested the
360 DDIs of the reference set.
Results
DDI information in NDF-RT, DrugBank and the reference set
Table 1 summarizes the number of DDIs in the three
data sets.
Reference set
The reference set contained 360 DDIs; all the drugs
mapped to RxNorm and were all classified as ingredi-
ents. The 360 DDIs covered 86 RxNorm ingredients.
DrugBank
DrugBank contained 12,128 DDIs defined in the XML
file. DDIs involving drugs with no mapping to RxNorm
were discarded (418 DDIs involving 46 drugs). Analysis
of all the discarded DDIs revealed several reasons why
the DDIs were eliminated. Some DDIs involved drugs
that were either withdrawn from public use (e.g., cerivas-
tatin, ephedra, heptabarbital) or not approved by the
U.S. Food and Drug Adminstration (e.g., cinolazepam,
carbetocin) and those drugs could not be mapped toTable 1 DDI counts in the three datasets
Data set DDI counts
Total from source Mapped to RxNorm Normalized
Reference 360 360 360
DrugBank 12128 11762 11552
NDF-RT 10831 9452 9392RxNorm. Additionally, 518 DrugBank DDIs were elimi-
nated through the ingredient normalization process. For
example, the DDIs containing zuclopenthixol, zuclo-
penthixol acetate and zuclopenthixol deconoate were
normalized to produce a single set with zuclopenthixol
as the ingredient, eliminating the redundant pairs con-
taining the salt forms. The resulting 11,552 normalized
DDIs covered 1153 RxNorm ingredients.
NDF-RT
NDF-RT contained 10,831 DDIs extracted from the data
set. DDIs involving drugs with no mapping to RxNorm
were discarded (1379 DDIs involving 38 drugs). Analysis
of all the discarded DDIs revealed that some DDIs were
associated with drugs which referenced obsolete RxNorm
concepts, many of these vaccine drugs that were recently
removed from RxNorm. Additionally, 60 NDF-RT DDIs
were eliminated through the ingredient normalization
process. The resulting 9,392 normalized DDIs covered
1079 RxNorm ingredients.
In the remainder of this paper, DDIs refer to pairs of
object and precipitant drugs normalized to RxNorm in-
gredients. However, even after normalization to RxNorm
ingredients, the coverage of drugs is not expected to be
the same in NDF-RT and DrugBank. For example, vac-
cines and other biologicals are present in NDF-RT, but
out of scope for DrugBank. When analysing DDIs across
the two sources, breakdown by pharmacological classes
will reflect such differences in drug coverage.
Comparing interactions across sources
The matching DDIs between the three data sets are
shown in Table 2.
Overlap between DrugBank and NDF-RT
Overall, the 2801 DDIs common to NDF-RT and Drug-
Bank represent a 30% coverage rate of NDF-RT by
DrugBank and a 24% coverage rate of DrugBank by
NDF-RT. Example of common DDIs include diltiazem/
lovastatin and itraconazole/sirolimus. Examples of DDIs
in DrugBank only include acebutolol/Insulin Lispro and
metronidazole/terfenadine. Examples of DDIs in NDF-
RT only include amiodarone/sotalol and meperidine/
linezolid.
When we only consider DDIs from the reference set,
the overlap between DrugBank and NDF-RT is significantlyTable 2 Matching DDIs across data sets
Data set Number of matching DDIs
Reference DrugBank NDF-RT
Reference 360 211 207
DrugBank 211 11552 2801
NDF-RT 207 2801 9392
Table 3 Reference Set DDI and coverage in NDF-RT and DrugBank










60 30 (50%) 30 (50%) Dexmethylphenidate, Dextroamphetamine, Methylphenidate,
Lisdexamfetamine, Phendimetrazine, Pseudoephedrine,
Amphetamine, Benzphetamine, Diethylproprion, Phentermine,
Atomoxetine, Methamphetamine
Tranylcypromine, Phenelzine, Isocarboxazid, Procarbazine,
Selegiline
4 Atazanavir – Proton
pump inhibitors (PPIs)
5 5 (100%) 5 (100%) Atazanavir Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Esmoprazole
8 Fluoxetine - MOA
inhibitors
55 39 (71%) 43 (78%) Fluoxetine, Paroxetine, Citalopram, Escitalopram,
Sertraline, Fluvoxamine, Duloxetine, Nefazodone,
Desvenlafaxine, Milnacipran, Venlafaxine
Tranylcypromine, Phenelzine, Isocarboxazid, Procarbazine, Selegiline
11 Irinotecan –
Ketoconazole
23 1 (4%) 5 (22%) Irinotecan Ritonavir, Nelfinavir, Atazanavir, Indinavir, Saquinavir, Amprenavir,
Darunavir, Lopinavir, Tipranavir, Fosamprenavir, Clarithromycin,
Erythromycin, Telithromycin, Amiodarone, Verapamil, Diltiazem,
Ketoconazole, Itraconazole, Fluconazole, Voriconazole, Nefazodone,
Aprepitant, Cimetidine
16 Narcotic analgesics –
MAO inhibitors
30 25 (83%) 15 (50%) Meperidine, Methadone, Tapentadol, Fentanyl,
Tramadol, Dextromethorphan
Tranylcypromine, Phenelzine, Isocarboxazid, Procarbazine, Selegiline
22 Ramelteon-fluvoxamine 4 0 (0%) 2 (50%) Ramelteon Fluvoxamine, Amiodarone, Ticlopidine, Ciprofloxacin
23 Rifampin – ritonavir 60 41 (68%) 25 (42%) Bosentan, Rifapentine, Carbamazepine, Rifabutin,
Rifampin, St. John’s wort
Ritonavir, Nelfinavir, Atazanavir, Indinavir, Saquinavir, Amprenavir,
Darunavir, Lopinavir, Tipranavir, Fosamprenavir
25 HMG Co-A reductase
inhibitors – protease
inhibitors
40 38 (95%) 33 (83%) Simvastatin, Lovastatin Ritonavir, Nelfinavir, Atazanavir, Indinavir, Saquinavir, Amprenavir,
Darunavir, Lopinavir, Tipranavir, Clarithromycin, Erythromycin,
Telithromycin, Amiodarone, Verapamil, Diltiazem, Tranylcypromine,




60 13 (22%) 35 (58%) Ritonavir, Nelfinavir, Atazanavir, Indinavir, Saquinavir,
Amprenavir, Darunavir, Lopinavir, Tipranavir,
Clarithromycin, Erythromycin, Telithromycin,
Ketoconazole, Itraconazole, Voriconazole
Ergotamine, Methylergonovine, Dihydroergotamine, Ergonovine
28 Tizanidine –
ciprofloxacin




1 1 (100%) 1 (100%) Tranylcypromine Procarbazine
31 Triptans – MAO
inhibitors
15 8 (53%) 11 (73%) Sumatriptan, Zolmitriptan, Rizatriptan Tranylcypromine, Phenelzine, Isocarboxazid, Moclobamide,
Methylene blue
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DrugBank represent 71% of the 207 reference DDIs cov-
ered by NDF-RT and 69% of the 211 reference DDIs cov-
ered by DrugBank.
Reference set coverage
Table 3 shows the breakdown by the reference set
groups of the DDI mapping for DrugBank and NDF-RT.
DrugBank contained 211 DDIs (59%) from the reference
set, compared with 207 DDIs (58%) for NDF-RT. There
were 146 DDIs (42%) from the reference set which were
both in the NDF-RT and DrugBank, including diltia-
zem/lovastatin, simvastatin/amiodarone and atazana-
vir/omeprazole. Conversely, there were 88 DDIs (24%) in
the reference set which were not contained in either
DrugBank or NDF-RT, including irinotecan/indinavir,
ketoconazole/ergonovine and milnacipran/selegiline.
DrugBank contained 65 DDIs from the reference set
which were not in NDF-RT (e.g., lovastatin/tipranavir
and ramelteon/fluvoxamine), and NDF-RT contained 61
DDIs from the reference set not in DrugBank (e.g., flu-
oxetine/procarbazine and simvastatin/saquinavir). Drug-
Bank had coverage in all groups from the reference set,
though only 100% coverage in two groups. NDF-RT had
coverage of all but one group (#22 ramelteon-fluvox-
amine). The coverage of the reference set of drug-drug
interactions by DrugBank and NDF-RT is available as
Additional file 1.
Of the 86 drugs contained in the reference set, one
(moclobamide, involved in 3 DDIs) did not exist in NDF-
RT and two (dexmethylphenidate, involved in 5 DDIs and
methylene blue, involved in 3 DDIs) did not exist in Drug-
Bank. In addition, there were four other drugs (bosentan,
lopinavir, methadone and zileuton) which were present inTable 4 Top ATC Class Counts in NDF-RT and DrugBank
NDF-RT






Non-selective monoamine reuptake inhibitors 311
Other antidepressants 309
Protease inhibitors 1130
Protein kinase inhibitors 759
Selective immunosuppressants 307
Selective serotonin reuptake inhibitors 341
Triazole derivatives 427
Vitamin K antagonists 292
*Boldface values indicate the ten top categories in each source.DrugBank, but not involved in any of the DDIs from the
reference set. DrugBank did have DDIs for these four
drugs outside of the reference set.
Pharmacologic classes
We mapped the DDIs from NDF-RT and DrugBank to
4th-level ATC drug classes to see if there were distinctive
class differences between the two sets of DDIs. A small
proportion of the drugs, such as avanafil, lopinavir and
zileuton (14% in NDF-RT, 11% in DrugBank) were not
represented in ATC and the corresponding DDIs were
excluded from the analysis.
Table 4 shows the top frequency count of ATC classes
for NDF-RT and DrugBank DDIs, along with the num-
ber of drugs from each class represented in the source
of DDI. For example, NDF-RT has 401 DDIs involving
11 drugs for the fluoroquinolone class, while DrugBank
has 335 interactions involving 14 drugs for this class.
Fluoroquinolones is in the top-10 classes for the fre-
quency of DDIs in NDF-RT, but not in DrugBank. Two
classes, protein kinase inhibitors and selective immuno-
suppressants, seem underrepresented in DrugBank,
while three classes, anticholinesterases, hydantoin deriv-
atives and non-selective monoamine reuptake inhibitors,
seem underrepresented in NDF-RT.
Table 5 shows the ATC pairs containing the most
DDIs from NDF-RT and DrugBank, but a low propor-
tion of shared DDIs between the two sources (evidenced
by the low Jaccard scores). The Adrenergic and dopa-
minergic agents - Non-selective monoamine reuptake in-
hibitors class pair, for example, has no NDF-RT DDIs
and 78 DrugBank DDIs. Examples in this class pair in-
clude dopamine/amitriptyline and norepinephrine/amox-















Table 5 Top ATC Class Pairs
ATC Class Pair total DDIs NDF-RT only DrugBank only both Jaccard
Protease inhibitors - Protein kinase inhibitors 103 72 10 21 0.20
Benzodiazepine derivatives - Protease inhibitors 88 5 52 28 0.32
Adrenergic and dopaminergic agents - Non-selective monoamine reuptake inhibitors 78 0 78 0 0
Antibiotics - Other quaternary ammonium compounds 71 35 8 28 0.39
Penicillins with extended spectrum - Tetracyclines 63 0 58 5 0.08
Protein kinase inhibitors - Triazole derivatives 60 32 10 18 0.30
Beta blocking agents, non-selective - Sulfonamides, urea derivatives 56 10 14 32 0.57
Macrolides - Protein kinase inhibitors 56 27 14 15 0.27
Figure 1 Frequency of DDIs in prescription pairs.
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exist in NDF-RT, such as boceprevir/bosutinib, than in
DrugBank. Finally, the Beta blocking agents, non-
selective - Sulfonamides, urea derivatives class pair illus-
trates a situation where both sources share a majority of
DDIs, but also have a significant number of specific
DDIs. For example, sotalol/glyburide is common, but
sotalol/tolazamide is specific to NDF-RT and sotalol/gli-
clazide is specific to DrugBank.
Comparing coverage of interactions from actual
prescription data
From the prescription dataset, almost 35.9 million pairs
were extracted, representing 816,258 unique pairs of
RxNorm clinical drugs. Restricted to systemic drugs, the
dataset included 35.5 million pairs of clinical drugs
(808,285 unique). Each clinical drug maps to at least one
ingredient, and multi-ingredient drugs map to several in-
gredients, resulting in multiple ingredient pairs for a
given pair of clinical drugs. For example, starting from
the pair of clinical drugs Primidone 250 MG Oral Tablet
and Carbidopa 25 MG/Levodopa 100 MG Oral Tablet,
we generate the following two pairs of ingredients, (Pri-
midone, Carbidopa) and (Primidone, Levodopa), because
the clinical drug Carbidopa 25 MG/Levodopa 100 MG
Oral Tablet maps to two ingredients, Carbidopa and
Levodopa. After mapping of the clinical drugs to ingredi-
ents, there were 45.2 million pairs of co-prescribed
drugs, ranging in frequency between 1 and 158,515 (me-
dian = 18). Of these, 808,285 pairs matched with NDF-
RT DDIs (2153 unique), while 1,170,693 pairs matched
with DrugBank DDIs (2823 unique). There were 382,833
pairs that matched with both NDF-RT and DrugBank
(988 unique). There were 26,672 matches with the refer-
ence set (88 unique). Figure 1 shows the frequency of
the DDIs (in parenthesis) with the unique number of
DDIs found in the prescription dataset.
Examples of frequently co-prescribed drugs identified
as a DDI by both NDF-RT and DrugBank include Diltia-
zem/Lovastatin and Clarithromycin/Simvastatin. Co-
prescribed drugs identified as a DDI by NDF-RT, butnot DrugBank include Amlodipine/Simvastatin and Dil-
tiazem/Oxycodone. Conversely, DDIs identified by Drug-
Bank, but not NDF-RT, include Amoxicillin/Ethinyl
Estradiol and Hydrochlorothiazide/Insulin Lispro. Table 6
shows the most frequently co-prescribed pairs recog-
nized as a DDI by one or both of the sources.
Publicly available vs. commercial DDI sources
We were able to match 328 (91%) DDIs of the reference
set to Multum DDIs, a significantly higher proportion
compared to NDF-RT and DrugBank. The level of sever-
ity provided by Multum for these DDIs (on a 3-level
scale mild, moderate or major) was consistent with the
notion of “high-severity” claimed by the authors of the
reference set, since 302 DDIs were rated major and the
other 26 were rated moderate.
Discussion
In this section, we discuss some of the reasons for the
limited overlap of DDI information among sources. We
also analyse its implications for our interactions API.
Limited overlap between NDF-RT and DrugBank DDIs
Findings
One important finding of this investigation is the limited
overlap (<30%) between DrugBank and NDF-RT DDIs,
Table 6 Top DDI Pairs found in Prescription Data
Drug pair Freq DrugBank DDI NDF-RT DDI
Amlodipine-Simvastatin 76980 X
Glipizide-Metoprolol 15469 X X
atorvastatin-Fenofibrate 14897 X X
Fenofibrate-Simvastatin 14060 X X
Albuterol-Metoprolol 14030 X
Insulin Glargine-Metoprolol 13492 X
Metoprolol-Sertraline 13311 X
atorvastatin-Diltiazem 13218 X X
Digoxin-Furosemide 12958 X




Diltiazem-Simvastatin 11484 X X
Alprazolam-Fluoxetine 11194 X
Sertraline-Trazodone 11066 X
Amoxicillin-Ethinyl Estradiol 11044 X
Lisinopril-Spironolactone 10248 X X
Clonazepam-Fluoxetine 10149 X
Fenofibrate-rosuvastatin 9954 X X
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of DDIs. We found 6591 DDIs specific to NDF-RT and
8751 specific to DrugBank, while only 2801 DDIs were
common to both sources. Differences in scope (e.g., the
lack of vaccine DDIs in DrugBank) account for only a
small portion of the differences. Differential coveragepersisted after abstracting DDIs to the corresponding
drug classes from ATC. For example, NDF-RT had many
more DDIs than DrugBank for Protease inhibitor drugs,
and had much fewer DDIs for Anticholinesterases drugs.
Likewise, many ATC class pairs had a small proportion
of DDIs in common, evidenced by low Jaccard scores.
For example, among the 56 DDIs for the Macrolides -
Protein kinase inhibitors class pair, only 15 are common
to NDF-RT and DrugBank (Jaccard = 0.27). The low
overlap rate also applied to our more frequently pre-
scribed drug pairs in the prescription data set. When we
examined the co-prescribed drugs from the prescription
data set, we found significant differences in identification
of DDIs between the two sources for the most frequently
co-prescribed pairs. Of the top 10 most frequently pre-
scribed drug pairs identified as potential DDIs by Drug-
Bank, only 5 were recognized as NDF-RT DDIs (see
Table 6 for details).
DDI severity
We wondered if the differential coverage observed be-
tween NDF-RT and DrugBank could be due in part to
different editorial guidelines for curating less severe
DDIs, assuming the most severe DDIs would be covered
more consistently by both sources. This did not seem to
be the case since the 360 high-severity DDIs from the
reference set are only partially covered by NDF-RT and
DrugBank. While NDF-RT provides an indication of se-
verity (critical or significant) for its DDIs, DrugBank
does not. Nevertheless, we tested if DrugBank would
cover a larger proportion of NDF-RT critical DDIs. In
fact, DrugBank DDIs accounted for 31% of the total crit-
ical DDIs in NDF-RT and for 29% of the total significant
DDIs. In other words, there is no difference in the cover-
age of NDF-RT by DrugBank in terms of DDI severity.
(Even when correcting for the absence of vaccine DDIs
in DrugBank, the overlapping DDIs accounted for just
40% of the critical DDIs in NDF-RT.)
Differential coverage of DDIs among sources
Our finding of limited overlap between NDF-RT and
DrugBank should not be surprising given similar find-
ings in studies comparing drug knowledge bases for crit-
ically important DDIs [21]. There is no standardization
for what constitutes a drug-drug interaction, and DDI
curators have to consider a variety of drug and patient
specific factors in their decision to include pairs of drugs
in their DDI lists. These factors include the severity of
the interaction, the probability of the interaction, patient
characteristics (e.g., specific patient groups, such as eld-
erly patients), and evidence supporting the interaction
(quantity of evidence, as well as the quality of the evi-
dence). The number of factors to consider makes this a
complex and daunting task. Moreover, the maintenance
Peters et al. Journal of Biomedical Semantics  (2015) 6:19 Page 9 of 10of DDI lists itself is an issue, as additional evidence for
or against DDIs becomes available over time. Finally, dif-
ferent strategies for prioritizing the various factors also
accounts for some of the differences observed across
sources.
Implications for the interactions API
Overall, our investigation of NDF-RT and DrugBank as
sources of DDIs for our API provides a mixed picture.
Not only do they both provide incomplete coverage of
the reference set (about 60% each), but their overlap is
also limited (42%). A similar difference could be ob-
served when we simulated interaction detection based
on actual usage data. We also confirmed that a commer-
cial source, Multum, provided a more systematic cover-
age of the reference set.
With the provision of DDI information being discon-
tinued in NDF-RT in November 2014, we decided to use
DrugBank as a replacement for our interactions API.
This solution is far from ideal, because this investigation
did not establish the accuracy of either source, but sim-
ply assessed differences among them. On the other hand,
DDI determination is not an exact science and both
NDF-RT and DrugBank provide valuable information to
support medical decision. NDF-RT DDIs are associated
with levels of severity, while DrugBank’s come with a
short description. In practice, the absence of severity
levels in DrugBank is a disadvantage, as severity is an
important consideration for determining when to alert
physicians to a potential DDI. Severity is also a require-
ment when checking DDI in the context of the Mean-
ingful Use incentive program.
It is important to keep in mind that no clinical deci-
sion system, as good as it is, can be a substitute for med-
ical advice. Our API not only clearly discloses the origin
of the information it provides, but also reminds our
users to seek advice from health professionals before
making decisions about their medications. In the future,
we plan to perform a more systematic and qualitative in-
vestigation of publicly available and commercial DDI
sources in order to better assess the differences among
these sources.
Conclusions
This study is the first comparative investigation of DDI
information in two publicly available sources, NDF-RT
and DrugBank. We compared the two sources not only
to themselves, but also to a reference set of DDIs, and
assessed their ability to identify DDIs in a large prescrip-
tion dataset. We also contrasted NDF-RT and DrugBank
against the commercial source Multum.
This investigation confirms the limited overlap be-
tween DDI information between NDF-RT and Drug-
Bank, even for the reference dataset. Additional researchis required to determine which source is better, if any.
Usage of any of these sources in clinical decision systems
should clearly disclose these limitations.
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